2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 609

Peripheral Neuropathy in Systemic Lupus Erythematosus
Abstract Number: 1489

Peripheral Neuropathy: A Complication of Systemic Sclerosis
Abstract Number: 1929

Pernicious Anemia and Vitamin B-12 Deficiency in Autoimmune Disease: Neglecting the Feet Will Lead You Astray
Abstract Number: 832

Peroxisome Proliferator-Activated Receptor Gamma Agonist Treatment for Rheumatoid Arthritis: A Proof-of-Concept Randomized Controlled Trial
Abstract Number: 379

Persistency and Predictors of Persistency of Adalimumab Among Rheumatoid Arthritis (RA) Patients in a US Registry
Abstract Number: 1433

Persistent Dyslipidemia Is a Risk Factor of Progression to Chronic Kidney Disease in Patients with Lupus Nephritis
Abstract Number: 2173

Pharmacoeconomic Evaluation of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1515

Pharmacological Blockade of Adenosine A2A Receptors (A_2AR) Prevents Radiation-Induced Dermal Injury
Abstract Number: 1907

Pharmacological Management of Gout in Italy in the Years 2005-2009: A Nationwide, Population-Based Study
Abstract Number: 1144

Phenotypic Characterization of Childhood Onset Rheumatoid Arthritis
Abstract Number: 2192

Phenotypic Features of Sjögren’s Syndrome Among Patients with Low-Titer SSA/B Antibodies
Abstract Number: 51

Phosphodiesterase 4 Expression in Rheumatoid Arthritis Synovium and Anti-Inflammatory Effects of Apremilast On Synovial Fibroblasts
Abstract Number: 1750

Phosphoprotein Changes Induced with Epratuzumab, an Antibody Targeting CD22 On B Cells
Abstract Number: 1585

Physical Activity and Timing of Discharge From Physical Therapy Following Total Knee Replacement
Abstract Number: 2634

Physical Disability, Perceived Dependence and Depression in Older Women with Osteoarthriti

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].